The U.S. trade deal with India, whose negotiations have been ongoing for years, is near finishing, and might be finalized in three to four months, a senior American trade official said on the sidelines of a regional summit here this week, repeating a comforting refrain. The other hole, the official said, is a consequence of "unresolved differences" between Washington and New Delhi. It's all about the paperwork that's required to pass through Washington's bureaucracy the paperwork in question being a series of Section 301 investigations that must run their course before anyone can put pen to paper.

That is the only caveat to entertain: it encapsulates just about everything peculiar about this negotiation. Two commerce ministers, who have called the “ substance” of the agreement essentially settled, have now been missing a rotating cast of self-imposed deadlines for more than a year. It was promised a signing would happen in March. Then a target of "fall 2025." Then a 90-day time limit that is connected with a tariff break. Both sides spoke with the same confidence now being offered about the coming three to four months, each one of them. It's evolved into a separate narrative, one larger maybe than the deal itself.

This time the mechanical challenge is a real one. In March, one of the Section 301 probes which includes India and sixty other economies was opened to assess whether governments are failing to take sufficient measures to prevent goods produced by forced labour. The findings published in June suggested a further tariff of 10 or 12.5 per cent for the countries, India included, who suffered the impact, more than 50 countries from Japan and Israel to Vietnam and Saudi Arabia. The lighter rate was for six countries with forced labour bans that are poorly implemented, such as those of the European Union and Canada. Since then, the Indian government, represented by its trade directorate in New Delhi, has tried to stem the tide of forced-labour exports, making a defensive move directly at the steepest number. A parallel inquiry into overcapacity in the industrial sector, mainly concerning steel and manufacturing, is underway. Washington is right that the entire transaction shouldn't be put on hold until these probes are finished, which should be done in days, if not sooner, on at least one front.

That decision, which has more to do with unsettling Indian industry than the forced-labour tariff, runs parallel to all this. Generic products coming into the U.S. will continue to be free of duty for two years from August, followed by a 100 percent duty for one year starting around 2029. This particular order is not applicable to branded and patented drugs. However, India supplies about two-fifths of the generic pills that Americans take for hypertension, diabetes and infectious disease and pharmaceuticals shipped to the US are worth nearly ten billion dollars annually, which is almost a third of India's global drug export book of nearly twenty-six billion dollars. In the Indian policy world, the two-year period is being viewed not as a time for relief but as an opportunity to bargain for an exception to the bilateral deal or quietly to see the thin-margin generics manufacturers expire. While Washington cannot afford to take this market supply chain away overnight which New Delhi does have some leverage over margins on standard generics are already extremely thin, meaning that even a partial tariff will likely force some manufacturers out of certain lines of business well before the next 200 percent takes effect.

The relationship between the two is a trading one and is too big to take lightly behind the headlines. Last year, the value of goods traded between the two countries was around $149 billion, with an increase in American imports from India of nearly 19 percent to $104 billion, and the US trade deficit with India increased to around $58 billion. Add services, and total bilateral trade is now worth over $240 billion, with India being the US's tenth largest trading partner and the US being the largest single market for India, accounting for almost one-fifth of India's exports. In joint statements, both governments have established a public goal of doubling that flow to $500 billion by 2030. The current baseline rate on Indian goods entering the United States is approximately 18 percent, down from the 25 percent rate that was floated briefly, and much less severe than the much more stringent numbers threatened during the tariff row of the last two years, following the Supreme Court's decision to invalidate the entire reciprocal tariff system.

In that context, the mid-2026 date seems more like a new date in an ongoing negotiation that has been captured by Washington's own overlapping trade process. All of the big American trading partners – Brazil, South Korea, Switzerland, etc. are keeping an eye on the same clock, and India's fate here is as much a function of world trade politics as it is of anything that happens in New Delhi. From the Indian exporters' perspective, especially those in the pharmaceuticals, textiles and engineering goods industry, the issue is no longer whether it will be signed up eventually. It's whether it comes on time and if it has enough “carve-outs” to make a difference before the next batch of American tariff deadlines begins to bite first.